



IN THE SPECIFICATION

Please replace the paragraph on page 1, lines 6-16 with the following amended paragraph:

The present invention relates to compounds of the formula I,



in which B, R_0 , Q, X, R_0 ; Q; X; Q' , D, R_{10} and V have the meanings indicated below.

The compounds of the formula I are valuable pharmacologically active compounds.

They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (Fxa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their



FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Please replace the paragraph at page 2, line 33, to page 3, line 2, with the following amended paragraph.

Thus, the present invention relates to compounds of the formula I,



wherein

Please replace the paragraphs at page 3, lines 23-28, with the following amended paragraphs:

2. (C_1-C_6) -alkylen (C_1-C_6) -alkylene , wherein alkylen alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or hydroxy group,



B3/CN

3. (C₃-C₆)-cycloalkylen (C₃-C₆)-cycloalkylene , wherein cycloalkylen cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or hydroxy group,

b7k

Please replace the paragraph at page 4, lines 1-2, with the following amended paragraph:

the substructure of formula III



wherein B, together with D and the two carbons to which D is attached,

b7k

Please replace the paragraph at page 9, lines 4-6, with the following amended paragraph:

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

BS

2. (C_1-C_4) -alkylen (C_1-C_4) -alkylene, wherein alkylen alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or hydroxy group,

Please replace the paragraph at page 10, lines 24-25, with the following amended paragraph:

BS

X is (C_1-C_3) -alkylen (C_1-C_3) -alkylene, wherein alkylen alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, amino group or hydroxy group,


Please replace the line at page 12, line 7, with the following amended line:

B7

X is (C_1-C_3) -alkylen (C_1-C_3) -alkylene,

Please replace the paragraph at page 24, lines 16-27, with the following amended paragraph:

For example, for the preparation of a compound of the formula I a building block of the formula XI,



in which R_0 , Q, Q', X, are as defined above for the compounds of the formula I but functional groups can optionally also be present in the form of precursor groups or can be protected by protective groups known to those skilled in the art, e.g. an amino group can be protected with a tert.-butyloxycarbonyl group or a benzyloxycarbonyl group. R^1 , $R^{1''}$, $R^{1'''}$, $R^{1''''}$, are defined as hydrogen or as R^1 which has the same meaning as in formula I but can optionally also be present in the form of precursor groups or can be protected by protective groups known to those skilled in the art, e.g. a hydroxy group may be attached to a polystyrene resin, and Y is a nucleophilically substitutable substitutable leaving group or a hydroxyl group, is reacted with a fragment of the formula III



H-NR₁₀-V (XII)

in which R_{10} and V are as defined above for the compounds of the formula I but functional groups can optionally also be present in the form of precursor groups or can be protected by protective groups.

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com